Andere talen Sino Biopharmaceutical Limited

Aandelen

1177

KYG8167W1380

Farmaceutische producten

Beurs gesloten - Hong Kong S.E. Andere beurzen 09:08:35 15-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,500 ^HKD	-4,41%		-4,97%	+103,12%

12/12	Sino Biopharmaceuticals borstkankermedicijn krijgt goedkeuring voor Chinese markt	MT
12/12	Culmerciclib-capsule van Sino Biopharmaceutical goedgekeurd voor de markt door NMPA	RE

Andere talen

Sino Biopharmaceutical's Breast Cancer Drug Gets China Nod for Marketing	12/12
Sino Biopharmaceutical says Culmerciclib capsule approved by NMPA for marketing	12/12
Suzhou Sanegene Bio Inc. announced that it has received $110 million in funding from a group of investors	09/12
Sino Biopharm Gets China, US FDA Nods for Weight Loss Drug Trials	04/12
Sino Biopharmaceutical says TQF3250 clinical trial approved by NMPA and FDA	04/12
Sino Biopharmaceutical Limited Announces Application for Its Self-Developed Innovative Drug, Tqf3250 Capsules "Orally Administered, Recommended for Weight Loss	04/12
Sino Biopharmaceutical Gets Marketing Nod for Rotigotine Patch	04/12
Sino Biopharmaceutical says rotigotine patch approved for marketing in China	03/12
Sino Biopharmaceutical Limited Announces "Rotigotine Patch" Approval by the National Medical Products Administration of China	03/12
Tuoji Pharmaceutical Co., Ltd. announced that it has received $60 million in funding from a group of investors	21/11
Sino Biopharmaceutical's Unit Gets Trial Approval for Anti-Tumor Drug in China	18/11
Sino Biopharmaceutical says LM-350 CDH17 antibody-drug conjugate receives clinical trial approval from China's NMPA	18/11
Sino Biopharmaceutical Limited Announces Application for Clinical Trial on LM-350 "CDH17 ADC" Approved by the NMPA	18/11
US Shutdown End, FX, Earnings Nudge Asian Markets Higher	13/11
I-Mab Announces Chief Financial Officer Changes, Effective October 16, 2025	16/10
Sino Biopharm's Plexiform Neurofibromas Drug Gets Breakthrough Therapeutic Designation in China	15/10
Sino Biopharmaceutical Limited Announces Inclusion of TQ-B3234 Selective Mek1/2 Inhibitor in the Breakthrough Therapy Designation Process	15/10
Sino Biopharmaceutical's Colorectal Cancer Drug Receives Breakthrough Therapeutic Designation in China	14/10
Sino Biopharmaceutical Limited Announces TQB2102 "Her2 BISPECific ADC" Included in the Breakthrough Therapeutic Designation Process	13/10
Sino Biopharmaceutical says TQB2102 included in breakthrough therapeutic designation process in China	13/10
Sino Biopharm Completes First Patient Enrollment of Anti-Tumor Drug Trial in Australia	25/09
Sino Biopharmaceutical Limited Announces Completion of Enrollment of the First Patient in the Phase I Clinical Trial of LM-350 'CDH17 ADC' in Australia	25/09
Sino Biopharmaceutical Limited Announces Completion of Enrollment of the First Patient in the Phase 1 Clinical Trial of Lm-2417 "Napi2b/4-1Bb Bispecific Antibody" in China	23/09
Sino Biopharm Enrolls First Patient in Tumor Drug Trial in China	23/09
Sino Biopharmaceutical says IND application for TQF3250 accepted by NMPA	22/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Sino Biopharm CEO Eric Tse over vooruitzichten, Aziatische farmaceutische markt & Trump

23 januari 2025 om 14:41 uur